AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for U6 snRNA phosphodiesterase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BQ65

UPID:

USB1_HUMAN

Alternative names:

3'-5' RNA exonuclease USB1; Mutated in poikiloderma with neutropenia protein 1

Alternative UPACC:

Q9BQ65; B4DWE3; B4DZW5; Q96FZ9; Q9H8X8

Background:

U6 snRNA phosphodiesterase 1, also known as 3'-5' RNA exonuclease USB1, plays a crucial role in RNA processing. It trims the 3' end of oligo(U) and oligo(A) tracts of pre-U6 small nuclear RNA (snRNA), leading to mature U6 snRNA formation. This protein is essential for U6 snRNA 3' end processing, preventing its degradation and ensuring the stability of RNA molecules involved in critical cellular functions.

Therapeutic significance:

Given its pivotal role in RNA processing and stability, U6 snRNA phosphodiesterase 1 is linked to Poikiloderma with neutropenia, a genodermatosis characterized by skin abnormalities and increased susceptibility to infections. Understanding the role of U6 snRNA phosphodiesterase 1 could open doors to potential therapeutic strategies for treating this disorder and possibly other RNA-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.